Technical Analysis for PSTI - Pluristem Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 1.12 0.00% 0.00
PSTI closed unchanged on Friday, January 18, 2019, on 31 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Feb 5

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical PSTI trend table...

Date Alert Name Type % Chg
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 NR7-2 Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Narrow Range Bar Range Contraction 0.00%
Jan 17 NR7 Range Contraction 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Overbought Stochastic Strength 0.00%
Jan 16 Narrow Range Bar Range Contraction 0.90%

Older signals for PSTI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Pluristem Therapeutics Inc., a bio-therapeutics company, engages in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of life threatening diseases. The company's products are derived from human placenta that is a non-controversial, non-embryonic, and adult cell source. Its Placental adherent stromal cells are grown in the company's proprietary PluriX three-dimensional process that allows cells to grow in a natural environment. The company develops placenta expanded cells (PLX) and peripheral artery disease cells, an allogeneic therapeutic product that is in Phase-II clinical trials for the treatment of intermittent claudication, critical limb ischemia, and Buerger's disease. Its PLX product is developed for the treatment of muscle injury, bone marrow diseases, inflammatory bowel disease, and multiple sclerosis, as well as for pulmonary disorders, acute radiation syndrome, acute myocardial infarction, diabetic diastolic heart failure, neuropathic pain, inflammatory bowel disease, multiple sclerosis, and ischemic stroke for which the product is in various pre-clinical trials. Pluristem Therapeutics Inc. is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is headquartered in Haifa, Israel.
Is PSTI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.6
52 Week Low 0.66
Average Volume 290,225
200-Day Moving Average 1.2128
50-Day Moving Average 1.0129
20-Day Moving Average 0.9591
10-Day Moving Average 1.095
Average True Range 0.0601
ADX 31.83
+DI 29.5355
-DI 16.5261
Chandelier Exit (Long, 3 ATRs ) 0.9697
Chandelier Exit (Short, 3 ATRs ) 0.8403
Upper Bollinger Band 1.2666
Lower Bollinger Band 0.6516
Percent B (%b) 0.76
BandWidth 64.122615
MACD Line 0.0452
MACD Signal Line 0.021
MACD Histogram 0.0242
Fundamentals Value
Market Cap 109.17 Million
Num Shares 97.5 Million
EPS -0.32
Price-to-Earnings (P/E) Ratio -3.50
Price-to-Sales 0.00
Price-to-Book 6.15
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.14
Resistance 3 (R3) 1.14 1.13 1.13
Resistance 2 (R2) 1.13 1.13 1.13 1.13
Resistance 1 (R1) 1.13 1.13 1.13 1.13 1.13
Pivot Point 1.12 1.12 1.12 1.12 1.12
Support 1 (S1) 1.12 1.12 1.12 1.12 1.11
Support 2 (S2) 1.11 1.12 1.11 1.11
Support 3 (S3) 1.11 1.11 1.11
Support 4 (S4) 1.11